Who Owns Mounjaro — and What That Means for UK Patients

The biggest misconception: Mounjaro and tirzepatide are not the same thing in name alone

A common assumption is that Mounjaro is simply a brand wrapper slapped over a generic compound anyone could make. It isn't. Tirzepatide is a novel, patented molecule, a dual agonist that activates both the GIP and GLP-1 gut-hormone receptors simultaneously. No other weight-loss medicine licensed in the UK works this way. Eli Lilly spent over a decade and billions of dollars developing and trialling it across the SURMOUNT and SURPASS clinical programmes, involving thousands of adults worldwide. The patent protection means that, for now, only Lilly can manufacture the active ingredient legally. You'll sometimes see the question framed as who actually owns the tirzepatide drug, the answer is the same: Eli Lilly holds the intellectual property, the synthesis process and the marketing authorisation.

This isn't a technicality. It shapes every practical aspect of accessing Mounjaro in the UK: which pharmacies can legally stock it, how the supply chain is structured, and why "generic tirzepatide" is not yet a thing you can buy. When a seller online claims to offer tirzepatide outside that chain, they are operating outside the authorised supply network, regardless of what they call their product.

How Lilly's ownership translated into UK approval

The MHRA granted Lilly a UK marketing authorisation for Mounjaro following extensive review of the SURMOUNT clinical trial data. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults and reported average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks. NICE subsequently appraised the evidence and recommended tirzepatide for NHS use under Technology Appraisal 1026, published in December 2024. That recommendation only covers Mounjaro, there is no licensed alternative brand of tirzepatide in the UK to recommend.

Because Lilly holds the licence, it also controls the list price. Lilly raised that UK list price significantly from 1 September 2025, with widely reported figures placing the highest-dose pen's list price at around £330 per four-week pen, up from roughly £122 previously. If you want to understand how those list-price changes have filtered through to private prescription costs, the background on the Lilly price increase is worth reading. Ownership, in short, is not just a legal footnote: it sets the floor on what you'll pay.

Who makes the physical pen, and why the supply chain matters

Lilly manufactures the tirzepatide drug substance and oversees production of the KwikPen delivery device. Each pen contains four weekly doses and is designed as a single-use, pre-filled subcutaneous injector. The physical production happens across Lilly's global manufacturing network, with medicines entering the UK through the licensed supply chain before reaching GPhC-registered pharmacies.

This chain is the line between genuine and counterfeit. The MHRA has warned publicly about fake pens (some containing insulin rather than tirzepatide) circulating online and via social media. Buying from a seller that cannot trace its stock back through authorised distribution is genuinely dangerous, not just legally grey. A pharmacy you can verify on the GPhC register is your clearest signal that the supply chain is intact. At nume, medicines are sourced through Lilly's authorised UK supplier relationships, that's a practical consequence of working within the licensed system Lilly's ownership defines.

Storage matters too, in a way that's easy to overlook: the KwikPen needs to be refrigerated between 2°C and 8°C. Many people keep theirs in the fridge door alongside everyday items, which is fine provided the temperature stays within range, the Mounjaro Patient Information Leaflet gives the exact permitted room-temperature window if you need to travel or be away from a fridge temporarily.

Lilly, Novo Nordisk and the wider ownership landscape of GLP-1 medicines

Eli Lilly is not the only company in this space. Novo Nordisk, a Danish pharmaceutical firm, owns the semaglutide molecule and markets it in the UK as Wegovy (for weight management) and Ozempic (for type 2 diabetes). Semaglutide works differently from tirzepatide (it targets only the GLP-1 receptor rather than both GIP and GLP-1) and the two medicines are covered by separate patents and separate MHRA licences. If you're weighing up the options, the full tirzepatide overview covers the clinical differences in more depth, and our treatment overview sets out what's available through a regulated private route.

The question of which company owns Mounjaro sometimes comes up when people are trying to verify whether a seller is legitimate. The honest answer is that only Lilly-authorised supply is genuine, and understanding who Mounjaro is intended for can also help you assess whether a seller's claims add up. If you're at the stage of considering whether Mounjaro might be clinically suitable for you, starting a free consultation with our prescribers is a straightforward next step, there's no obligation, and a GPhC-registered prescriber reviews every application personally.